Hi synaphai , sorry but my opinion regarding FDA approvals differs substaintialy to yours and I dare say you have not been involved with many if any Aust companies involved in dealing with the FDA as I am aware your in the US The other issue you fail to mention is regarding taking on the likes of Medtronic’s / Edwards and others in marketing DurAVR a single product as they have substaintial product lines . AHZ. / AVR has already had a taste of this with another ADAPT product Cardicel . At that time AHZ had very little capital at that time but without causing massive dilution I can’t see this being possible considering who were would taking on , GLTATH
AVR Price at posting:
$18.10 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
